Showing posts with label Tachycardia. Show all posts
Showing posts with label Tachycardia. Show all posts

Monday, March 10, 2014

Overview of Multifocal Atrial Tachycardia

Multifocal atrial tachycardia (MAT) is a cardiac arrhythmia caused by multiple sites of competing atrial activity. It is characterized by an irregular atrial rate greater than 100 beats per minute (bpm). Atrial activity is well organized, with at least 3 morphologically distinct P waves, irregular P-P intervals, and an isoelectric baseline between the P waves.

Shine, Kastor and Yurchak first proposed this definition of MAT in 1968.[1] MAT has previously been described by terms such as chaotic atrial rhythm or tachycardia, chaotic atrial mechanism, and repetitive paroxysmal MAT.

Usually, treatment of the patient's underlying problem (eg, respiratory failure, sepsis, theophylline toxicity) takes therapeutic precedent. The condition is transient and resolves when the underlying condition improves.

For more information, see Atrial Tachycardia

NextPathophysiology of MAT

The mechanism of the arrhythmia has not been well defined. Delayed afterdepolarizations leading to triggered automaticity are postulated to result in the development of multifocal atrial tachycardia (MAT). The evidence that implicates this mechanism is mainly indirect and points to intracellular calcium overload by various mechanisms (eg, catecholamine excess, phosphodiesterase inhibition, acidosis, hypoxemia). Electrolyte imbalances associated with severe underlying illnesses can further potentiate the development of this arrhythmia. MAT most often is found in the elderly patient with decompensated chronic lung disease and should be thought of as a hypoxic complication of underlying heart conduction pathology. However, other underlying causes may be present, such as heart failure, sepsis, or methylxanthine toxicity. The effect of MAT on the heart’s conduction system may or may not lead to hemodynamic instability.

PreviousNextEtiology of MAT

Causes of multifocal atrial tachycardia (MAT) are mainly related to underlying illnesses. The following common underlying illnesses are associated with this arrhythmia:

Decompensated chronic lung diseaseCoronary artery diseaseHeart failureValvular heart diseaseDiabetes mellitusHypokalemiaHypomagnesemiaAzotemiaPostoperative statePulmonary embolism PneumoniaSepsisMethylxanthine toxicityPreviousNextEpidemiology of MAT

Multifocal atrial tachycardia (MAT) is a relatively infrequent arrhythmia, with a prevalence rate of 0.05-0.32% in patients who are hospitalized. It is predominantly observed in males and in older patients—in particular, elderly patients with multiple medical problems. The average age of patients from 9 studies was 72 years.

Patients with MAT frequently have significant comorbidities, especially chronic obstructive pulmonary disease (COPD) and respiratory failure, and are often treated in ICUs. Consequently, a high mortality rate (ie, up to 45%) is associated with this arrhythmia, although it is not a direct consequence of the rhythm abnormality.

MAT is seldom life threatening. The overall clinical picture and symptoms improve when the underlying condition is addressed and MAT is controlled. Morbidity is difficult to quantify because the underlying disease is the primary determinant of complications.

PreviousNextClinical PresentationPatient history

Patients may complain of a variety of symptoms, or more rarely, the disease may be asymptomatic. The most common complaints include the following:

PalpitationsShortness of breathChest painLightheadednessSyncopal episode

These symptoms may be transient.

Physical examination

Physical examination findings are typically related to the underlying disease process and are not specific for MAT. The pulse is rapid and irregular,[2] and the first heart sound may be variable. The physical examination is not typically sufficient to differentiate multifocal atrial tachycardia from atrial fibrillation. Respiratory adventitial sounds often are prominent.

Depending upon comorbid conditions or general health status, the patient may be hemodynamically unstable. However, determining whether this is due to the underlying condition or the dysrhythmia may be difficult.

Complications

Potential acute complications of MAT include the following:

Atrial thrombi with embolization and subsequent strokeMyocardial infarction from incongruous myocardial supply and demandPulmonary emboliUnderlying disorders

COPD is the most common underlying disease process, seen in approximately 60% of MAT cases. MAT is commonly precipitated by exacerbation of COPD, sometimes due to infection or cardiac decompensation. Increasing hypoxemia with respiratory acidosis and advanced disease also leads to increased bronchodilator usage, thereby increasing catecholamine levels, which may contribute to development of MAT.

Patients with MAT frequently have cardiac diseases, mainly coronary artery disease and valvular heart diseases, often in conjunction with COPD. Heart failure is often present when the diagnosis of MAT is first made.

In various series, 24% of patients with MAT were found to have diabetes mellitus. Fourteen percent had hypokalemia, and 14% had azotemia. Twenty-eight percent of patients with MAT were recovering from major surgery, while others had postoperative infections, sepsis, pulmonary embolism, and heart failure.

The link between pulmonary embolism and MAT is weak (ie, 6-14% of such patients have been said to have MAT), but the methods of diagnosing pulmonary embolism have not been well documented.

Experimental evidence demonstrates that IV cocaine use may lead to the development of MAT.

PreviousNextDifferential Diagnosis

The differential diagnosis of MAT includes atrial fibrillation and atrial flutter. Clear differentiation of multifocal atrial tachycardia (MAT) from atrial fibrillation is very important because the treatment of atrial fibrillation differs from that of MAT. MAT with aberration or preexisting bundle branch block may be misinterpreted as ventricular tachycardia. MAT must also be differentiated from other tachyarrhythmias, both narrow-complex and wide-complex, including sinus tachycardia with frequent premature atrial contractions (PACs).

PreviousNextElectrocardiography

The diagnosis of multifocal MAT is confirmed with an ECG that displays the following features (see the image below):

Irregular ventricular rate greater than 100 bpmOrganized and discrete P waves with at least 3 different morphologies in the same electrocardiographic leadIrregular PP, PR, and RR intervals with an isoelectric baseline between the P wavesECG showing multifocal atrial tachycardia (MAT). ECG showing multifocal atrial tachycardia (MAT).

Some authors have suggested that patients who have a heart rate less than 100 bpm but who satisfy all other criteria (including the clinical profile commonly observed with MAT) be considered to have multifocal atrial rhythm, or multifocal atrial bradycardia if the rate is less than 60 bpm. There is controversy about whether this condition should be referred to as a MAT variant or a wandering atrial pacemaker, although patients with wandering atrial pacemaker usually do not have serious underlying illnesses.

The requirement that 3 different P waves should exist has been applied since early descriptions of the arrhythmia were recorded, but whether this should be interpreted as 2 ectopic P waves and 1 sinus P wave or 3 ectopic P waves has been a matter of controversy. The consensus favors a minimum of 3 different waveforms in addition to sinus P waves.

Baseline noise on the ECG can mimic atrial fibrillation and can obscure differences in P wave morphology. Conversely, coarse atrial fibrillation on short recordings may appear to show discrete P waves prior to each QRS complex. Longer ECG recordings are therefore useful.

PreviousNextLaboratory Studies

Laboratory testing mainly consists of the following:

Serum chemistry panel to exclude electrolyte disordersBlood hemoglobin level and RBC counts to seek evidence of anemiaArterial blood gases to define pulmonary status

Any further testing depends on the underlying disease process (eg, cardiac biomarkers in patients with coronary artery disease, or a theophylline level if patient has been prescribed, or has access to, this medication).

PreviousNextOther Tests

Consider a portable anteroposterior (AP) chest radiograph to evaluate for pulmonary and cardiac findings, particularly in the unstable patient. All patients should be placed on pulse oximetry and a cardiac monitor.

PreviousNextTreatment of MATPrehospital care

The following measures should be taken in the prehospital setting:

Assess for pulmonary causes that may be causing the arrhythmiaStabilize the acute situation as necessaryProvide oxygen, cardiac monitoring, and pulse oximetryEstablish IV access without delaying transportCollect medications that the patient may be taking or may have access toEmergency department care

Rapidly assess and stabilize the ABCs while providing simultaneous treatment. An upright sitting position usually is most appropriate. Obtain IV access with a large-bore catheter and give isotonic sodium chloride solution at a to-keep-open (TKO) rate.

Administer oxygen to maintain the saturation greater than 90%, but avoid excessive oxygen in patients with known significant chronic obstructive pulmonary disease (COPD). This will avoid the theoretical problem of removing the hypoxic drive for ventilation, which can result in increased carbon dioxide retention.

The need for tracheal intubation is dictated by the standard clinical indications.

Establish cardiac monitor, blood pressure monitor, and pulse oximetry.

Assess for and treat the underlying cardiopulmonary process, theophylline toxicity, or metabolic abnormality. Administer bronchodilators and oxygen for treatment of decompensated COPD; activated charcoal and/or charcoal hemoperfusion is the therapy for theophylline toxicity. When magnesium sulfate is administered to correct hypokalemia, most patients convert to normal sinus rhythm. Avoid sedatives.

Treatment and/or reversal of the precipitating cause may be all that is required for patients with multifocal atrial tachycardia (MAT); however, the arrhythmia may recur if the underlying condition worsens. Moreover, treatment of underlying diseases may sometimes have arrhythmia-promoting effects; for example, theophylline and beta-agonist drugs used in patients with COPD produce an increased catecholamine state. These therapies should be used judiciously.

Calcium channel blockers

Diltiazem[3] and verapamil[4, 5, 6, 7, 8, 9] decrease the atrial activity and slow atrioventricular (AV) nodal conduction, thereby decreasing ventricular rate, but they do not return all patients to normal sinus rhythm. Transient hypotension is the most common adverse effect, which may often be avoided by pretreating the patient with 1 g of intravenous calcium gluconate (10 mL of 10% calcium gluconate).

Diltiazem may be used as a 20-45 mg intravenous bolus and then as a 10-25 mg/h continuous infusion. Verapamil may worsen hypoxemia by negating the hypoxic pulmonary vasoconstriction in underventilated alveoli; this is usually not clinically significant.

Beta-blockers

More patients convert to a normal sinus rhythm when treated with beta-blockers. However, the use of beta-blockers is limited by transient hypotension and by bronchospastic adverse effects, since lung disease is commonly associated with MAT.

Metoprolol[6, 8, 10, 11, 12] has been used to lower the ventricular rate. Both oral and intravenous dosage forms have been used. The oral dosage is 25 mg q6h until the desired effects are obtained. Intravenous bolus dosing has been administered to as much as 15 mg over 10 minutes.

Although no controlled studies have evaluated the use of short-acting beta-blockers in treatment of MAT, esmolol can also be used to control the ventricular rate as an intravenous infusion. It has a very short half-life and can be terminated quickly in the event of an adverse reaction.

Magnesium

In a small number of patients, high-dose magnesium[6, 13, 14, 15, 16] causes a significant decrease in the patient's heart rate and conversion to normal sinus rhythm. The dosage is 2 g intravenously over 1 minute, followed by 2 g/h infusion over 5 hours.

Antiarrhythmics

Amiodarone[17, 18, 19] (300 mg PO tid or 450-1500 mg IV over 2-24 h) has been used and has been reported to be associated with conversion to normal sinus rhythm. The success rate was 40% at 3 days with oral dosing and 75% on day 1 with intravenous dosing; however, this has been evaluated in a very small number of patients. Recent data support the use of amiodarone prophylactically postoperatively in patients with COPD. Case reports have also supported the use of ibutilide[20] and flecainide[21] for cardioversion.

Digitalis

Despite the urge to use digoxin, it has not been found to be effective in controlling the ventricular rate or restoring normal sinus rhythm. Digoxin promotes afterdepolarizations, which may promote the arrhythmia. Ventricular arrhythmias, AV block, and death have been reported when excessive digoxin has been administered to patients who were incorrectly diagnosed with atrial fibrillation.

Cardioversion

Cardioversion is contraindicated in MAT. Due to the multiple atrial foci, direct current (DC) cardioversion is not effective in restoring normal sinus rhythm and can precipitate more dangerous arrhythmias.

Surgical care

In patients who have persistent and recurrent episodes of MAT and problems with rate control, the AV node may be ablated using radiofrequency energy and a permanent pacemaker implanted.[22] This approach should be considered both for symptomatic and hemodynamic improvement and to prevent the development of tachycardia-mediated cardiomyopathy.

Consultations

A cardiologist may be of assistance with ECG interpretation and may be available for consultation if antiarrhythmic therapy is being considered.

Inpatient care

Most patients with MAT require admission to further manage their underlying cardiopulmonary diseases. These patients frequently are admitted to a monitored bed; however, the clinical scenario and the hemodynamic stability of the patient dictate disposition.

Further outpatient care

Patients who convert to normal sinus rhythm after treatment and stabilization of the underlying process or provision of specific antiarrhythmic therapy may be cautiously considered for discharge. In order to be discharged, the patient must be back to baseline condition, have no complicating factors, be able to accomplish activities of daily living, and be available for close follow-up care.

Deterrence/prevention

The best means of prevention of MAT is prevention of respiratory failure plus careful monitoring of all electrolyte disorders, namely, hypokalemia, hypomagnesemia, and drug therapy (mainly digoxin toxicity). In patients receiving theophylline, careful monitoring of drug levels is important in order to avoid toxicity.

Patient education

Education about the causes of this arrhythmia may be beneficial. In the case of a pulmonary source, education about prevention and recognition of developing pulmonary conditions may be helpful. In the case of MAT related to medication use, education regarding the correct use and how to monitor such medications should be considered.

Previous, Multifocal Atrial Tachycardia

Sunday, March 9, 2014

Background

Tachycardia is an abnormal rapidity of heart action that usually is defined as a heart rate more than 100 beats per minute (bpm) in adults. In children, the normal heart rate is age dependent, and the definition of tachycardia varies, as shown below.[1, 2]

Age 1-2 days - 123-159 bpmAge 3-6 days - 129-166 bpmAge 1-3 weeks - 107-182 bpmAge 1-2 months - 121-179 bpmAge 3-5 months - 106-186 bpmAge 6-11 months - 109-169 bpmAge 1-2 years - 89-151 bpmAge 3-4 years - 73-137 bpmAge 5-7 years - 65-133 bpmAge 8-11 years - 62-130 bpmAge 12-15 years - 60-119 bpmNextPathophysiology

The heart is innervated primarily by the vagus nerve and the sympathetic ganglion. Pain sensation travels through afferent fibers associated with the sympathetic ganglia. In most patients, the sensation of a normal heartbeat is not felt. Some children may complain of palpitations or rushing or pounding in the ears.

PreviousProceed to Clinical Presentation , Pediatric Tachycardia

Wednesday, March 5, 2014

Practice Essentials

Most sudden cardiac deaths in the United States are caused by ventricular tachycardia (VT) or ventricular fibrillation (VF), at an estimated rate of approximately 300,000 deaths per year. Ventricular tachycardia refers to any rhythm faster than 100 beats per minute, with 3 or more irregular beats in a row, arising distal to the bundle of His. The rhythm may arise from working ventricular myocardium and/or from the distal conduction system.

Essential update: Safety and efficacy of complete endocardial VT substrate ablation after MI

Complete endocardial ventricular tachycardia substrate ablation (CEVTSA) is safe and effective in patients with previous myocardial infarction (MI), even in those in whom VT substrate has not been identified, according to a study of 59 post-myocardial infarction patients by Arenal and colleagues. Dense scar area and VT cycle length were significant independent predictors of VT recurrence.[1, 2]

Signs and symptoms

History

The symptoms of ventricular tachycardia include the following:

PalpitationLight-headednessSyncopeChest painAnxiety

Physical examination

During VT, the following symptoms may be observed:

HypotensionTachypneaSigns of diminished perfusion: Including a diminished level of consciousness, pallor, and diaphoresisHigh jugular venous pressureCannon a waves: If the atria are in sinus rhythmVariation in intensity of first heart sound: Due to loss of atrioventricular (AV) synchrony

Following conversion, physical findings during normal sinus rhythm are related to any underlying structural heart disease.

VT can also result in sudden death. Patients in whom this occurs may first present with syncope.

See Clinical Presentation for more detail.

Diagnosis

Assess levels of serum electrolytes, including the following, in all patients with VT:

Calcium: Ionized calcium levels are preferred over total serum calcium levelsMagnesiumPhosphate

Hypokalemia, hypomagnesemia, and hypocalcemia may predispose patients to either monomorphic VT or torsade de pointes.

Laboratory studies can also include the following:

levels of therapeutic drugs, such as digoxinToxicology screens: May be helpful in those cases related to recreational drug useSerum cardiac troponin I or T levels or other cardiac markers: To evaluate for myocardial ischemia or infarction

VT at acute presentation

In patients who have VT at acute presentation and who are unconscious or hemodynamically unstable, the diagnosis is made from the physical findings and electrocardiogram (ECG) rhythm strip.

If circumstances allow, a full 12-lead electrocardiogram should be obtained prior to urgent cardioversion.

Laboratory studies are impractical, and advanced cardiac life support (ACLS) protocols must be quickly followed. However, in patients who have VT at acute presentation and are hemodynamically stable, a 12-lead ECG and electrolytes may be obtained prior to attempted conversion with medications or sedation and cardioversion.

VT postconversion

In patients with VT postconversion, diagnosis proceeds as follows:

Repeat the ECG after termination of VTInclude electrolyte levels in an acute evaluationPerform toxicology screens for cocaine metabolites and tricyclic antidepressants: In accordance with the patient’s clinical history Check cardiac enzyme levels: If clinical symptoms or signs of ischemia are presentPerform echocardiography and coronary angiography: Following conversion to sinus rhythm, to assess for structural and ischemic heart disease

Electrophysiologic study

Diagnostic electrophysiologic study (EPS) requires placement of electrode catheters in the ventricle, followed by programmed ventricular stimulation using progressive pacing protocols. EPS is particularly relevant in patients who are felt to be at high risk for sudden death due to significant underlying structural heart disease.

See Workup for more detail.

Management

Medications

The mainstays of treatment for clinically stable VT are the various antidysrhythmic drugs. Intravenous medications are used to suppress acute monomorphic VT; in the United States, these are limited to the following agents:

ProcainamideLidocaineAmiodaroneBeta-adrenergic blocking agents metoprolol, esmolol, and propranolol

ICDs

American College of Cardiology/American Heart Association/European Society of Cardiology (ACC/AHA/ESC) guidelines recommend implantable cardioverter-defibrillator (ICD) therapy for primary prevention to reduce total mortality by a reduction in sudden cardiac death (SCD) in patients with the following characteristics[3] :

Left ventricular (LV) dysfunction due to previous myocardial infarction (MI)At least 40 days post-MILV ejection fraction (LVEF) of 30-40% or lessNew York Heart Association (NYHA) functional class II or IIIReceiving chronic optimal medical therapyReasonably expected to survive with good functional status for more than 1 year

Ablation

Endocardial catheter ablation is used early in idiopathic, monomorphic VT (ie, VT in a structurally normal heart) but can also be used to reduce arrhythmia burden in the presence of cardiomyopathy.

See Treatment and Medication for more detail.

Image libraryThis is a rapid monomorphic ventricular tachycardiThis is a rapid monomorphic ventricular tachycardia (VT), 280 beats per minute, associated with hemodynamic collapse. This tracing was obtained from a patient with severe ischemic cardiomyopathy during an electrophysiologic (EP) study. The rhythm later converted to sinus with a single external shock. This patient had an atrial rate of 72 beats per minute (measured with intracardiac electrodes, not shown). Although ventriculoatrial dissociation (faster V rate than A rate) is diagnostic of VT, the surface ECG findings (dissociated P waves, fusion or capture beats) are only present approximately 20% of the time. In this tracing, the ventricular rate is simply too fast for P waves to be observed. VT with cycle lengths from 200-240 ms is often termed ventricular flutter. NextBackground

Ventricular tachycardia (VT) refers to any rhythm faster than 100 (or 120) beats per minute arising distal to the bundle of His. The rhythm may arise from working ventricular myocardium and/or from the distal conduction system. (See Etiology.) Go to Pediatric Ventricular Tachycardia for complete information on this topic.

VT may be reflected in symptoms such as syncope, palpitations, and dyspnea. It is often, but not always, associated with hemodynamic compromise, particularly if the left ventricle is impaired or the heart rate is especially fast. With some exceptions, VT is associated with increased risk of sudden death. (See Etiology, Prognosis, History, Physical Examination, Workup.)

VT generally is a consequence of ischemic or structural heart disease or electrolyte deficiencies (eg, hypokalemia, hypocalcemia, hypomagnesemia). It can also be triggered by the following (see Etiology):

Use of sympathomimetic agents (from intravenous inotropes to illicit drugs such as methamphetamine or cocaine)Systemic diseases that affect the myocardium, such as sarcoidosis, systemic lupus erythematosus, hemochromatosis, and rheumatoid arthritisOther structural congenital disorders, such as right ventricular dysplasia and tetralogy of FallotDigitalis toxicity - Can lead to biventricular tachycardia.Inherited channelopathies[4] Drugs that prolong the QT complex (eg, type 1A antidysrhythmics, droperidol and related phenothiazines)

Drugs that prolong the QT complex may cause torsade de pointes. (See Etiology.)

Monomorphic and polymorphic ventricular tachycardia

VT may be monomorphic (originating from a single focus with identical QRS complexes) or polymorphic (may appear as an irregular rhythm, with varying QRS amplitudes and morphology). Examples of monomorphic and polymorphic VTs are seen below.

This is a rapid monomorphic ventricular tachycardiThis is a rapid monomorphic ventricular tachycardia (VT), 280 beats per minute, associated with hemodynamic collapse. This tracing was obtained from a patient with severe ischemic cardiomyopathy during an electrophysiologic (EP) study. The rhythm later converted to sinus with a single external shock. This patient had an atrial rate of 72 beats per minute (measured with intracardiac electrodes, not shown). Although ventriculoatrial dissociation (faster V rate than A rate) is diagnostic of VT, the surface ECG findings (dissociated P waves, fusion or capture beats) are only present approximately 20% of the time. In this tracing, the ventricular rate is simply too fast for P waves to be observed. VT with cycle lengths from 200-240 ms is often termed ventricular flutter. This is a slow monomorphic ventricular tachycardiaThis is a slow monomorphic ventricular tachycardia (VT), 121 beats per minute, from a patient with an old inferior wall myocardial infarction and well-preserved left ventricular function (ejection fraction [EF] 55%). He presented with symptoms of palpitation and neck fullness. Note the ventriculoatrial dissociation, most obvious in V2 and V3. Slower VT rates and preserved left ventricular (LV) function are associated with a better long-term prognosis. Polymorphic ventricular tachycardia. Polymorphic ventricular tachycardia. Sustained and nonsustained ventricular tachycardia

Nonsustained VT is defined as a run of tachycardia of less than 30 seconds duration; longer runs are considered sustained VT.

While nonsustained ventricular tachycardia is a frequently observed dysrhythmia, sustained, monomorphic ventricular tachycardia is uncommon in the emergency department (ED) setting due to aggressive treatment of myocardial ischemia.

When sustained VT causes signs or symptoms of diminished perfusion, emergent treatment is necessary.

Electrocardiography in ventricular tachycardia

No absolute electrocardiographic criteria exist for establishing the presence of VT. However, several factors suggest VT, including the following:

Rate greater than 120 beats per minute (usually 150-200)Wide QRS complexes (>140 ms; see the ECG below)Presence of atrioventricular (AV) dissociationFusion beatsCapture beatsThis patient is a 64-year-old man with a history oThis patient is a 64-year-old man with a history of prior myocardial infarction and syncope. In patients with prior myocardial infarction, the most common mechanism of wide QRS complex tachycardia is ventricular tachycardia. Myocardial scar tissue in ventricular tachycardia

The most common setting for VT is ischemic heart disease, in which myocardial scar tissue is the substrate for electrical reentry, but it can be seen in other conditions that create myocardial scar tissue, such as ion channel abnormalities, dilated cardiomyopathies, hypertrophic cardiomyopathy, right ventricular dysplasia, Chagas disease,[5] and surgical incisions in the ventricle.

Ventricular tachycardia versus ventricular fibrillation

VT is distinguished from ventricular fibrillation (VF), which is a grossly disorganized, rapid ventricular rhythm that varies in interval and waveform. VF may be difficult to distinguish from rapid, polymorphic VT. There is a potential definitional overlap with accelerated idioventricular rhythm when an automatic VT is noted from 100-120 beats per minute.

Sudden death accounts for approximately half of all deaths from cardiovascular disease and is generally caused by VT and VF.

PreviousNextPathophysiology

Regardless of the arrhythmia mechanism in ventricular tachycardia (VT), the severity of clinical symptoms determines the urgency with which VT must be treated.

During VT, cardiac output is reduced due to the rapid heart rate and lack of a properly timed or coordinated atrial contraction. Ischemia and mitral[6] insufficiency may also contribute to hemodynamic intolerance. Hemodynamic collapse is more likely when underlying left ventricular dysfunction is present or with very rapid rates. Diminished cardiac output may result in diminished myocardial perfusion, worsening inotropic response and degeneration to VF, resulting in sudden death.

In patients with monomorphic VT, mortality risk correlates with the degree of structural heart disease. Underlying structural heart diseases, such as ischemic cardiomyopathy, dilated cardiomyopathy, hypertrophic cardiomyopathy, Chagas disease, and right ventricular dysplasia, have all been associated with monomorphic or polymorphic VT degenerating to VF.[5]

Even without such degeneration, VT can also produce congestive heart failure and hemodynamic compromise, with subsequent morbidity and mortality.

If VT is hemodynamically tolerated, the incessant tachyarrhythmia may cause a dilated cardiomyopathy. This may develop over a period of weeks to months and resolves with successful management of the VT.[7] A similar course is occasionally seen with ventricular bigeminy, despite the absence of sustained high rates.

PreviousNextEtiology

Ventricular tachycardia (VT) is usually a consequence of structural or ischemic heart disease, with breakdown of normal conduction patterns. Abnormal automaticity (which tends to favor ectopic foci) or activation of reentrant pathways in the myocardium can exist to generate the dysrhythmia. Electrolyte disturbances, ischemia, and sympathomimetics may increase the likelihood of VT in the susceptible myocardium.

Atrioventricular dissociation

AV dissociation, shown in the ECGs below, is apparent in approximately half of VT episodes, and when present, it is a hallmark characteristic of VT.[8] This occurs because the sinus node is depolarizing the atria at a rate that is slower than the pathologic, faster ventricular rate. P waves can be visualized at times in between or embedded in the QRS complexes, but the P waves and QRS complexes have their own independent rates.

This ECG shows another form of idiopathic ventricuThis ECG shows another form of idiopathic ventricular tachycardia, seen in the absence of structural heart disease. This rhythm arises from the left ventricular septum and often responds to verapamil. Upon superficial examination, it appears to be a supraventricular tachycardia with bifascicular conduction block (RBBB/LAFB). Closer examination of lead V1 shows narrowing of the fourth QRS complex, consistent with fusion between the wide QRS complex and a conducted atrial beat, confirming AV dissociation and VT mechanism. AV dissociation. AV dissociation. Fusion and capture beats

Fusion beats and capture beats can occur in the presence of VT, depending on the refractory period of the AV node and the timing of ventricular and atrial depolarizations, respectively.

A fusion beat has a mixed morphology, due to normal AV node/His-Purkinje conduction occurring simultaneously with abnormal (a wide, complex QRS) ventricular depolarization. A normally conducted impulse travels from the AV node through the normal conduction pathway (a narrow QRS), and the competing impulse originates from the abnormal ectopic ventricular focus outside of the normal conduction pathway (a wide QRS). The two converge, leading to a mixed (fused) QRS.

A capture beat occurs when an atrial impulse arrives at the AV node at a "fortuitous" time, when the AV node has just recovered from its refractory period. The timing has to be just right, as the AV node is frequently in its refractory state due to depolarization caused by retrograde conduction from the rapid ventricular rhythm. When this occurs, conduction will proceed normally through the AV node/His-Purkinje system, "capturing" the ventricle and leading to a normal, narrow QRS complex. Fusion beats, capture beats, and AV dissociation are shown in the image below.

Fusion beats, capture beats, and AV dissociation. Fusion beats, capture beats, and AV dissociation.

Retrograde conduction can also exist from the ventricles to the atria via the AV node. This is not AV dissociation and reveals itself in an electrocardiogram (ECG) as a 1:1 correlation between the wide QRS complex and an inverted P wave, which follows the QRS complex.

Monomorphic ventricular tachycardia

When the ventricular activation sequence is constant, the electrocardiographic pattern remains the same, and the rhythm is called monomorphic VT (seen in the ECG below).

Monomorphic ventricular tachycardia. Monomorphic ventricular tachycardia.

Monomorphic VT is most commonly seen in patients with underlying structural heart disease. There is typically a zone of slow conduction, most commonly due to scarring and/or fibrillar disarray. Causes include prior infarct, any primary cardiomyopathy, surgical scar, hypertrophy, and muscle degeneration.

Reentrant tachycardias occur when an electrical wavefront travels slowly through the zone of slow conduction (usually damaged muscle protected by scar tissue), allowing the rest of the circuit time to repolarize. The wavefront breaks out of the scar, activates the ventricle, and reenters the slow conduction zone. The QRS morphology during VT can be used to predict the exit site from the zone of slow conduction.[9]

Although most patients with VT have underlying structural heart abnormalities, monomorphic VT is occasionally observed in patients with structurally normal hearts (idiopathic VT). These VTs are often exercise dependent, and their clinical behavior may be more consistent with triggered activity or abnormal automaticity.

Monomorphic VTs are typically named for their site of origin. The most commonly involved sites are the right ventricular outflow tract, left ventricular outflow tract, left ventricular septum, and aortic root.[10]

Although monomorphic VTs have classically been considered benign, sudden death may occur, albeit rarely, despite the presence of a structurally normal heart.[11]

Polymorphic ventricular tachycardia

When the QRS complex varies from beat to beat, the rhythm is described as polymorphic VT and suggests a variable electrical activation sequence. The most notorious, and probably the most common, form of polymorphic VT is torsade de pointes. The disorder’s name is a French term that suggests a "twisting of the points" of the QRS complexes over time

Torsade de pointes has unusual shifting-axis QRS complexes that appear (on ECGs) as if the heart is rotating upon an axis. It typically occurs during sinus rhythm and in the presence of drugs or conditions that prolong the QT interval (eg, type 1A antiarrhythmics, hypomagnesemia, droperidol). The dysrhythmia may occur either in the presence or in the absence of myocardial ischemia or infarction. Examples of torsade de pointes are shown below.

Torsade de pointes. This is a polymorphic ventricuTorsade de pointes. This is a polymorphic ventricular tachycardia (VT) associated with resting QT-interval prolongation. In this case, it was caused by the potassium channel blocker, sotalol. This rhythm is also observed in families with mutations affecting certain cardiac ion channels. Torsades de pointes. Torsades de pointes.

The term torsade de pointes is reserved for polymorphic VT observed in the setting of a prolonged QT interval. Other polymorphic VTs are occasionally observed during ischemia or myocarditis.

Acquired QT prolongation is observed with certain potassium channel–blocking medications. Most of the causative drugs block the delayed rectifier cardiac potassium current, IKr. These agents include quinidine, erythromycin, haloperidol, and many others.

Congenital long QT syndrome is a group of genetic disorders involving abnormal cardiac ion channels (most commonly potassium channels responsible for ventricular repolarization).

In acquired and congenital long QT syndromes, prolonged repolarization predisposes to torsade de pointes, which is most likely a reentrant rhythm with a constantly varying circuit. Other inherited ion channel abnormalities may cause idiopathic VF and familial polymorphic VT in the absence of QT prolongation.

Go to Torsade de Pointes for complete information on this topic.

Sustained and nonsustained ventricular tachycardia

The most common cause of sustained, monomorphic VT is a prior myocardial infarction (MI) with ventricular myocardial scar formation. The presence of myocardial fibrosis is a substrate for slow conduction pathways and associated reentry mechanisms.

Nonsustained VT and ectopy result from abnormal automaticity mechanisms and are more commonly associated with acute myocardial ischemia.

Idioventricular rhythm

A second variant of VT is accelerated idioventricular rhythm. Sometimes termed slow ventricular tachycardia, this dysrhythmia presents with a rate of 60-100 beats per minute. It typically occurs with underlying heart disease (ischemic or structural), is transient, and only rarely is associated with hemodynamic compromise or collapse. Treatment of the dysrhythmia itself usually is not required unless significant hemodynamic impairment develops.

Inherited dysrhythmia

Due to advances in molecular biology, a number of inherited dysrhythmic disorders with a propensity toward VT have been described. Brugada syndrome, congenital long and short QT syndromes, and catecholaminergic polymorphic VT have autosomal dominant inheritance patterns.[12, 13, 14, 15] Mechanistically, each disorder is characterized by imbalanced ion transport across the cardiac cellular membrane, which leads to abnormalities in cardiac repolarization and, consequently, increased risk of dysrhythmia. An autosomal recessive form of long QT syndrome is associated with increased arrhythmia risk and congenital hearing loss.

These syndromes have all been linked to sudden cardiac death. Patients with these disorders are managed with a combination of genetic typing, antidysrhythmic medications, lifestyle modification, and, in selected cases, implantable cardioverter-defibrillator (ICD) placement.[16]

Supraventricular tachycardia

Wide complex conduction during supraventricular tachycardia can mimic VT. The 2 most common forms of are (1) AV reentrant tachycardia (AVRT) and (2) AV nodal reentrant tachycardia with aberrant conduction (AVNRT).

AVRT can be either orthodromic or antidromic depending on the direction of conduction through the AV node. All antidromic AVRTs cause wide-complex tachycardia due to ventricular activation outside of the His-Purkinje system, and some orthodromic AVRTs conduct with wide QRS complexes as a result of functional or preexisting bundle-branch block or intraventricular conduction delay. Note the images below.

Retrograde P's #1 Retrograde P's #1 Retrograde P's #2. Retrograde P's #2.

Aberrantly conducted SVT circuits can mimic VT, but careful ECG analysis can allow discrimination of VT from aberrant SVT in most cases. See Electrocardiography for details.

Risk factors for ventricular tachycardia

Triggers of VT include electrolyte abnormalities, ischemia, inflammation, and sleep apnea.

Hypokalemia is the most important arrhythmia trigger clinically, followed by hypomagnesemia. Hyperkalemia may also predispose to VT and VF, particularly in patients with structural heart disease.

Certain genetic groups carry genetically mediated risk of unusual heart disease. Examples include the Veneto region of Italy and Greek island of Naxos (right ventricular dysplasia),[17] and northeastern Thailand (idiopathic ventricular fibrillation/Brugada syndrome).[18]

Ventricular tachycardia risk within populations generally varies with the risk factors for atherosclerosis, rather than ethnic differences per se.

Among patients younger than 35 years, the most common causes of sudden death, and presumably of VT, include hypertrophic cardiomyopathy, right ventricular cardiomyopathy, myocarditis, and long QT syndrome.

Risk factors for VT also include the following:

Use of sympathomimetic agents - From intravenous inotropes to illicit agents such as methamphetamine or, as previously mentioned, cocaine Drugs that prolong the QT complex (eg, type 1A antidysrhythmics, droperidol and related phenothiazines) - May infrequently cause torsade de pointes Systemic diseases that affect the myocardium, such as sarcoidosis, systemic lupus erythematosus, hemochromatosis, and rheumatoid arthritis Structural congenital disorders such as right ventricular dysplasia and tetralogy of FallotDigitalis toxicity - Can lead to biventricular tachycardiaInherited channelopathies[4]

The American College of Cardiology/American Heart Association / European Society of Cardiology (ACC/AHA/ESC) 2006 guidelines (the most current version available as of May 18, 2011) for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death recommend an antidigitalis antibody for patients with sustained ventricular arrhythmias, advanced AV block, and/or asystole caused by digitalis toxicity.[3]

PreviousNextEpidemiologyIncidence and mortality rate in the United States

The incidence of ventricular tachycardia (VT) in the United States is not well quantified because of the clinical overlap of VT with ventricular fibrillation (VF).

Examination of sudden death data provides a rough estimate of VT incidence. Most sudden cardiac deaths are caused by VT or VF, at an estimated rate of approximately 300,000 deaths per year in the United States, or about half of the estimated cardiac mortality in this country.

A prospective surveillance study gave a sudden death incidence of 53 per 100,000, accounting for 5.6% of all mortality.[19] This is only a rough estimate of VT incidence, because many patients have nonfatal VT and because arrhythmic sudden deaths may be associated with VF or bradycardia rather than with VT.

In patients with ischemic cardiomyopathy and nonsustained VT, sudden death mortality rates approach 30% in 2 years.

International incidence of ventricular tachycardia

Ventricular tachycardia and coronary artery disease are common throughout most of the developed world. In developing countries, ventricular tachycardia and other heart diseases are relatively less common.

Sex predilection

Ventricular tachycardia (VT) is observed more frequently in men, because ischemic heart disease is more prevalent among men. Among patients with coronary artery disease in the Framingham Heart Study, male deaths were more common than female deaths (46% vs 34%, respectively).[20]

Females with acquired or congenital long QT syndromes are at greater risk for sudden death. The opposite is true for arrhythmogenic right ventricular dysplasia (a 2-fold male predominance) and Brugada syndrome (an approximately 8-fold male predominance).

As coronary artery disease (CAD) becomes more common in women, it seems certain that the incidence of VT in women will increase.

Age predilection

The incidence of ischemic ventricular tachycardia (VT) increases with age, regardless of sex, as the prevalence of coronary artery disease increases.

VT is unusual among pediatric patients, although when present, it occurs in the postoperative cardiac setting or in patients with associated congenital heart disease. Tachydysrhythmias in this population generally are paroxysmal supraventricular tachycardias (PSVTs).

Ventricular tachycardia incidence rates peak in the middle decades of life, following the incidence of structural heart disease.

Idiopathic VT can be observed at any age.

Go to Pediatric Ventricular Tachycardia for complete information on this topic.

Morbidity and mortality in ventricular tachycardia

Morbidity and mortality in VT arise principally from spontaneous degeneration into the more malignant VF. (See Pathophysiology, above.) In patients with ischemic cardiomyopathy and nonsustained VT, sudden death mortality rates approach 30% in 2 years.

If VT is associated with hemodynamic collapse, morbidity in resuscitated survivors can include ischemic encephalopathy, acute renal insufficiency, transient ventricular dysfunction, aspiration pneumonitis, and trauma related to resuscitative efforts.

PreviousNextPrognosis

Prognosis in ventricular tachycardia (VT) varies with the specific cardiac process but is predicted best by left ventricular function.

As previously mentioned, in patients with ischemic cardiomyopathy and nonsustained VT, sudden-death mortality rates approach 30% in 2 years.

In patients with idiopathic VT, the prognosis is excellent, and the major risk is due to poorly timed syncopal spells.

A few exceptions exist to the left-ventricle rule. Patients with long QT syndrome, right ventricular dysplasia, and hypertrophic cardiomyopathy may be at increased risk of sudden death despite relatively preserved left ventricular function. These possibilities should be considered in any patient with a strong family history of premature sudden death.

PreviousNextPatient Education

For patient education information, see the Heart Center, as well as Heart Rhythm Disorders, Supraventricular Tachycardia, and Palpitations.

PreviousProceed to Clinical Presentation , Ventricular Tachycardia

Sunday, February 16, 2014

Background

A pacemaker-mediated tachycardia (PMT) can be defined as any condition in which a pacemaker paces the ventricles at rates that are inappropriately fast. This can be due to (1) a rate response setting that is too sensitive, (2) tracking of atrial noise (such as what may occur with electromagnetic interference), (3) inappropriate pacemaker manipulation with rate response turned on, or (4) tracking of an atrial tachyarrhythmia related to upper rate settings.

Traditionally, however, the term pacemaker-mediated tachycardia, also called endless-loop tachycardia, is used to refer to a form of a reentrant tachycardia and can occur in patients who have dual-chamber pacemakers. The pacemaker forms the anterograde (atrium to ventricle [A → V]) limb of the circuit and the atrioventricular (AV) node is the retrograde limb (ventricle to atrium [V → A]) of the circuit.[1] This classic form is referred to and discussed as PMT for the rest of this article.

ECG images below.

Telemetered ECG tracing with surface lead II (top)Telemetered ECG tracing with surface lead II (top) and intracardiac electrograms (atrial electrogram [center] and ventricular electrogram [lower]) and marker channel (bottom) showing pacemaker-mediated tachycardia (PMT). The intracardiac markers indicate that the retrograde P waves, labeled AS for atrial-sensed event, occur 280 milliseconds after the ventricular-paced beats, labeled VP. Telemetered ECG tracing showing atrioventricular (Telemetered ECG tracing showing atrioventricular (AV)–paced rhythm at 60/min after termination of the pacemaker-mediated tachycardia (PMT). The tracing, from top to bottom, shows lead II, atrial electrogram, ventricular electrogram, and marker channels. The intracardiac markers indicate the rhythm is atrial paced (AP) and ventricular paced (VP). Note that the VP beats are ventricular pseudofusion beats. This is a typical example of PMT with ventricular This is a typical example of PMT with ventricular pacing at maximum tracking rate (VP-MT) and then termination of the tachycardia as the atrial sensing (AS) is in the PVARP. This is due to PVARP extension, which is a feature of this particular pacemaker. The solid line indicates where PMT is detected and this is the point at which PVARP extension occurs. As this electrogram was detected, but not sensed to be acted upon, the ventricular tracking stopped and the tachycardia terminated. In some cases, pacemakers have a program to lengthen the PVARP after PMT detection to potentially stop the tachycardia. Alternatively, prevention of one ventricular paced beat can also stop the tachycardia. Some pacemakers use this algorithm. NextPathophysiology

The following is the most common scenario causing PMT. A dual-chamber pacemaker programmed DDD or VAT, but not DDI, is implanted. The patient must have retrograde (V → A) conduction with an atrial activation time that is longer than the programmed postventricular atrial refractory period (PVARP). A ventricular-paced beat or a properly timed premature ventricular contraction (PVC) conducts retrograde via the AV node (or an accessory pathway, if present) to the atrium. If the atrial depolarization occurs after the set PVARP, but before the next timed atrial-paced beat, ventricular pacing will be triggered at the programmed AV interval.

PMT tends to occur at or near the programmed upper rate limit and depend upon the programmed AV delay and the PVARP. This generates an incessant reentrant arrhythmia circuit that persists as long as there is continuous VA conduction with atrial activation outside the PVARP. The pacemaker forms the antegrade limb of the circuit and VA conduction forms the retrograde limb as the essential critical components.[1] In many instances, the PVARP varies so that it shortens with rate. This can make PMT more likely. The AV interval can be programmed to change with the rate. This tends to reduce the risk of PMT. Depending on the pacemaker programming and the VA conduction, the rate of the PMT may vary, but it is bounded by (and generally occurs near or at) the programmed upper rate limit.

While PMT is commonly initiated by an isolated ventricular ectopic beat, it can also be initiated by failure to capture the atrium with a paced beat followed by a ventricular paced beat. If this occurs, the atrium is then amenable to depolarization by the impulse conducted retrograde from the ventricle. The tachycardia continues until retrograde conduction ends or the atrium becomes refractory. Specific pacemaker algorithms may also terminate PMT if tracked rates persist at the upper rate limit. The pacemaker can be programmed to lengthen the PVARP after a PVC or with an incessant tachycardia at the upper rate limit or prevent one atrial sensed event from being tracked. Up to one third of patients with antegrade complete AV block have intact (or intermittent) retrograde (V → A) conduction.

Other situations that can result in PMT include intermittent atrial undersensing. An atrial premature beat with a long A sense-V pace interval (due to a long programmed AV interval) in a patient with heart block can also initiate PMT as any antegrade concealed depolarization otherwise present cannot prevent VA conduction in this instance.[2]

PreviousNextEpidemiologyMortality/Morbidity

Patients may experience palpitations, rapid heart rates, lightheadedness, syncope, or chest discomfort.

PreviousProceed to Clinical Presentation , Pacemaker-Mediated Tachycardia

Thursday, January 23, 2014

Practice Essentials

Atrial tachycardia is a supraventricular tachycardia (SVT) that does not require the atrioventricular (AV) junction, accessory pathways, or ventricular tissue for its initiation and maintenance. It occurs in persons with normal hearts and in those with structurally abnormal hearts, including individuals with congenital heart disease (particularly after surgery for repair or correction of congenital or valvular heart disease).

In patients with structurally normal hearts, atrial tachycardia is associated with a low mortality rate. Patients with underlying structural heart disease, congenital heart disease, or lung disease are less likely to be able to tolerate this rhythm disturbance.

Essential updates: Distinguishing between left- and right-sided atrial tachycardia

Patterns derived from combining pulmonary artery, right atrial, and coronary sinus potentials can be used to distinguish between left- and right-sided atrial tachycardia, according to a study by Hirai et al. Using sequences obtained using electrode and ablation catheters, the investigators were able to predict the presence of left-sided atrial tachycardia with 90% accuracy, as well as a sensitivity and specificity of 78% and 100%, respectively.[1]

Signs and symptoms

Manifestations of atrial tachycardia include the following:

Rapid pulse rate: In most atrial tachycardias, the rapid pulse is regular; it may be irregular in rapid atrial tachycardias with variable AV conduction and in multifocal atrial tachycardia (MAT) Episodic or paroxysmal occurrenceSudden onset of palpitationsContinuous, sustained, or repetitive tachycardia: If atrial tachycardia is due to enhanced automaticityWarm-up phenomenon: Tachycardia gradually speeds up soon after onset (may be clinically inapparent)Dyspnea, dizziness, lightheadedness, fatigue, or chest pressure: In tachycardic episodes accompanied by palpitationsSyncope: With rapid rate and severe hypotensionHeart-failure symptoms and reduced effort tolerance: Early manifestations of tachycardia-induced cardiomyopathy in patients with frequent or incessant tachycardia

In patients with MAT, the history may disclose an underlying illness that is causing the tachycardia. Such illnesses include pulmonary, cardiac, metabolic, and endocrinopathic disorders. Chronic obstructive pulmonary disease (COPD) is the most common underlying disease process (60%) in MAT.

Reentrant atrial tachycardia is not uncommon in patients with a history of a surgically repaired atrial septal defect. The scar tissue in the atrium may give rise to the formation of a reentrant circuit.

On physical examination, the primary abnormal finding is a rapid pulse rate. The rate is usually regular, but it may be irregular in rapid atrial tachycardias with variable AV conduction and in MAT. Blood pressure may be low in patients presenting with fatigue, lightheadedness, or presyncope.

See Clinical Presentation for more detail.

Diagnosis

Workup for atrial tachycardia can employ the following diagnostic tools:

12-lead electrocardiography: To help identify, locate, and differentiate atrial tachycardiaHolter monitoring: To analyze the onset and termination of atrial tachycardia, identify the AV conduction block during the episode, and correlate the symptoms to atrial tachycardia Endocardial mapping: To localize atrial tachycardia

The following laboratory studies may be indicated to exclude systemic causes of sinus tachycardia:

Serum chemistry: To exclude electrolyte disordersBlood hemoglobin level and red blood cell (RBC) counts: To seek evidence of anemiaArterial blood gas level: To define pulmonary statusSerum digoxin assay: When digitalis intoxication is suspected

The following imaging studies can be useful in the evaluation of patients with atrial tachycardia:

Chest radiography: In patients with tachycardia-induced cardiomyopathy or complex congenital heart diseaseComputed tomography (CT) scanning: To exclude pulmonary embolism, assess the anatomy of pulmonary veins, and provide images prior to ablative procedure Echocardiography: To rule out structural heart disease and assess left atrial size, pulmonary arterial pressure, left ventricular function, and pericardial pathology

See Workup for more detail.

Management

The primary treatment during a bout of atrial tachycardia is considered to be rate control using AV nodal blocking agents (eg, beta blockers, calcium channel blockers). Antiarrhythmic drugs can prevent recurrences and may be required; a calcium channel blocker or beta blocker also may be required in combination therapy. Specific antiarrhythmic therapies include the following:

Atrial tachycardia from triggered activity: Verapamil, beta blockers, and adenosineAtrial tachycardia from enhanced automaticity: Beta blockers, but overall success rates are lowRefractory recurrent atrial tachycardia: Class Ic antiarrhythmic drugsMaintenance of sinus rhythm: Class III antiarrhythmic drugs

Nonpharmacologic therapies for atrial tachycardia include the following:

Cardioversion: For patients in whom the rhythm is not well-tolerated hemodynamically and in whom rate-control drugs are ineffective or contraindicated Radiofrequency catheter ablation: For symptomatic, medically refractory patients[2, 3] Surgical ablation: For patients with complex congenital heart disease

Multifocal atrial tachycardia

Treatment of MAT involves treatment and/or reversal of the precipitating cause. Therapy also may include the following:

Calcium channel blockers: Used as the first line of treatmentMagnesium sulfate: When administered to correct hypokalemia, most patients convert to normal sinus rhythm (NSR)Beta blockersAntiarrhythmics

In very rare cases, when MAT is persistent and refractory, AV junctional radiofrequency ablation and permanent pacemaker implantation should be considered. Such treatment can provide symptomatic and hemodynamic improvement and prevent the development of tachycardia-mediated cardiomyopathy.[4]

See Treatment and Medication for more detail.

Image LibraryThis 12-lead electrocardiogram demonstrates an atrThis 12-lead electrocardiogram demonstrates an atrial tachycardia at a rate of approximately 150 beats per minute. Note that the negative P waves in leads III and aVF (upright arrows) are different from the sinus beats (downward arrows). The RP interval exceeds the PR interval during the tachycardia. Note also that the tachycardia persists despite the atrioventricular block. NextBackground

Atrial tachycardia is defined as a supraventricular tachycardia (SVT) that does not require the atrioventricular (AV) junction, accessory pathways, or ventricular tissue for its initiation and maintenance. Atrial tachycardia can be observed in persons with normal hearts and in those with structurally abnormal hearts, including those with congenital heart disease and particularly after surgery for repair or correction of congenital or valvular heart disease.

In adults, tachycardia is usually defined as a heart rate more than 100 beats per minute (bpm). In children, the definition of tachycardia varies because the normal heart rate is age dependent, as follows:[5, 6]

Age 1-2 days: 123-159 bpmAge 3-6 days: 129-166 bpmAge 1-3 weeks: 107-182 bpmAge 1-2 months: 121-179 bpmAge 3-5 months: 106-186 bpmAge 6-11 months: 109-169 bpmAge 1-2 years: 89-151 bpmAge 3-4 years: 73-137 bpmAge 5-7 years: 65-133 bpmAge 8-11 years: 62-130 bpmAge 12-15 years: 60-119 bpm

As in most SVTs, the electrocardiogram (ECG) typically shows a narrow QRS complex tachycardia (unless bundle branch block aberration occurs). Heart rates are highly variable, with a range of 100-250 bpm. The atrial rhythm is usually regular. (See the image below.)

This 12-lead electrocardiogram demonstrates an atrThis 12-lead electrocardiogram demonstrates an atrial tachycardia at a rate of approximately 150 beats per minute. Note that the negative P waves in leads III and aVF (upright arrows) are different from the sinus beats (downward arrows). The RP interval exceeds the PR interval during the tachycardia. Note also that the tachycardia persists despite the atrioventricular block.

The conducted ventricular rhythm is also usually regular. It may become irregular, however, especially at higher atrial rates, because of variable conduction through the AV node, thus producing conduction patterns such as 2:1, 4:1, a combination of those, or Wenckebach AV block.

The P wave morphology on the ECG may give clues to the site of origin and mechanism of the atrial tachycardia. In the case of a focal tachycardia, the P wave morphology and axis depend on the location in the atrium from which the tachycardia originates. In the case of macroreentrant circuits, the P wave morphology and axis depend on activation patterns (see Workup).

Multifocal atrial tachycardia (MAT) is an arrhythmia with an irregular atrial rate greater than 100 bpm. Atrial activity is well organized, with at least 3 morphologically distinct P waves, irregular P-P intervals, and an isoelectric baseline between the P waves.[7] Multifocal atrial tachycardia has previously been described by names such as chaotic atrial rhythm or tachycardia, chaotic atrial mechanism, and repetitive paroxysmal MAT. Go to Multifocal Atrial Tachycardia for more complete information on this topic.

Classification methods

A number of methods are used to classify atrial tachycardia. Classification in terms of origin can be based on endocardial activation mapping data, pathophysiologic mechanisms, and anatomy.

On the basis of endocardial activation, atrial tachycardia may be divided into the following 2 groups (see Presentation):

Focal atrial tachycardia: Arises from a localized area in the atria such as the crista terminalis, pulmonary veins, ostium of the coronary sinus, or intra-atrial septum. Reentrant atrial tachycardias: Usually macroreentrant; reentrant atrial tachycardias most commonly occur in persons with either structural or complex heart disease, particularly after surgery involving atrial incisions or scarring Other methods of classification are as follows:Pathophysiologic mechanisms: Atrial tachycardia can be classified as the result of enhanced automaticity, triggered activity, or reentry (see Pathophysiology) Anatomy: Classification of atrial tachycardia can be based on the location of the arrhythmogenic focus (see Anatomy)Diagnosis and treatment

A 12-lead ECG is an important tool to help identify, locate, and differentiate atrial tachycardia. Laboratory studies may be indicated to exclude systemic disorders that may be causing the tachycardia. Electrophysiologic study may be required. (See Workup.)

The primary treatment during a bout of atrial tachycardia is considered to be rate control using AV nodal blocking agents, such as beta blockers or calcium channel blockers (see Treatment and Medication). Cardioversion should be considered for any patient in whom the rhythm is not tolerated well hemodynamically and in whom rate control drugs are ineffective or contraindicated.

Radiofrequency catheter ablation for atrial tachycardia has become a highly successful and effective treatment option for symptomatic patients whose condition is refractory to medical therapy or who do not desire long-term antiarrhythmic therapy. It can cure macroreentrant and focal forms of atrial tachycardia. (See Treatment.)[8, 9]

PreviousNextAnatomy

Atrial tachycardia can have a right or left atrial origin. Some atrial tachycardias actually originate outside the usual anatomic boundaries of the atria, in areas such as the superior vena cava, pulmonary veins, and vein of Marshall, where fingers of atrial myocardium extend into these locations. Rare locations, such as the noncoronary aortic cusp[2] and hepatic veins, have been described, as well. (See the video below.)

Propagation map of right atrial tachycardia originating from the right atrial appendage obtained with non-contact mapping using EnSite mapping system.

A number of aspects of the atrial anatomy can contribute to the substrate for arrhythmia. The orifices of the vena cava, pulmonary veins, coronary sinus, atrial septum, and mitral and tricuspid annuli are potential anatomic boundaries for reentrant circuits.

Anisotropic conduction in the atria due to complex fiber orientation may create the zone of slow conduction. Certain atrial tissues, such as the crista terminalis and pulmonary veins, are common sites for automaticity or triggered activity. Additionally, disease processes or age-related degeneration of the atria may give rise to the arrhythmogenic substrate.

Abnormalities that have been reported at the sites of atrial tachycardia origin include the following[1] :

Extensive myocardial fibrosisMyocyte hypertrophyEndocardial fibrosisMononuclear cell infiltrationMesenchymal cell proliferationIslets of fatty tissueThinningBlebs PreviousNext, Atrial Tachycardia

Wednesday, January 22, 2014

Background

Atrioventricular nodal reentry tachycardia (AVNRT) is the most common type of reentrant supraventricular tachycardia (SVT). The substrate for AVNRT is the presence of dual AV nodal pathways. (See Etiology.)[1, 2]

Because of the abrupt onset and termination of the reentrant SVT, the nonspecific term paroxysmal supraventricular tachycardia (or even the misleading term paroxysmal atrial tachycardia [PAT]) has been used to refer to these tachyarrhythmias. With improved knowledge of the electrophysiology of reentrant SVT, greater specificity in nomenclature, based on the mechanism of reentry, has been possible. Such improved classification aids in the choice of appropriate therapies. (See Etiology, Prognosis, Treatment, and Medication.)

AVNRT is usually well tolerated, often occurring in patients with no structural heart disease. (See Prognosis, Presentation, and Workup.)

Patient education

Patients should be instructed on vagal maneuvers (Valsalva, diving reflex), used to try to terminate an episode of AVNRT. Patients with hemodynamic compromise or syncope should be instructed on avoiding activities that could be dangerous to them or to others (eg, driving, swimming) while the risk of an episode remains. Ablation obviates the need for any long-term restriction.

For patient education information, see the Heart Health Center, as well as Supraventricular Tachycardia.

NextEtiology

The substrate for AVNRT may be functional rather than anatomic. These arrhythmias occur in young, healthy patients and in those with chronic heart disease.

In patients with atrioventricular (AV) nodal reentry, the AV node is functionally divided into 2 longitudinal pathways that form the reentrant circuit. (In contrast to a bypass tract, dual AV nodal physiology is often an acquired abnormality.) In the majority of patients, during AVNRT, antegrade conduction occurs to the ventricle over the slow (alpha) pathway, and retrograde conduction occurs over the fast (beta) pathway. (See the image below.)

Electrophysiological mechanism of atrioventricularElectrophysiological mechanism of atrioventricular nodal reentry tachycardia.

In most patients with this arrhythmia, the tachycardia is initiated when an atrial premature complex is blocked in the fast pathway with a longer refractory period and conducts in the slow pathway with a shorter refractory period. While the impulse conducts to the ventricle in the slow pathway (antegrade conduction), the fast pathway recovers so that the impulse can conduct retrograde up the fast pathway to the atrium and the atrial end of the slow pathway (retrograde conduction).

In approximately one third of patients, AVNRT is induced by premature ventricular stimulation. In addition to the typical mechanism of AV nodal reentry described above, atypical AV nodal reentry can occur in the opposite direction, with antegrade conduction in the fast pathway and retrograde conduction in the slow pathway. Less commonly, the reentrant circuit can be over 2 slow pathways, the so-called slow-slow AV nodal reentry. (See the images below.)

Atypical atrioventricular nodal reentry tachycardiAtypical atrioventricular nodal reentry tachycardia. Typical atrioventricular nodal reentry tachycardiaTypical atrioventricular nodal reentry tachycardia. PreviousNextEpidemiology

In the United States, AVNRT occurs in 60% of patients (with a female predominance) presenting with paroxysmal SVT. The prevalence of SVT in the general population is likely several cases per thousand persons. Internationally, the occurrence of AVNRT is similar to that in the United States.

AVNRT may occur in persons of any age. It is common in young adults, but some patients do not present until their seventh or eighth decade or later.

PreviousNextPrognosis

The prognosis for patients with AVNRT is usually good in the absence of structural heart disease. Most patients respond to medications to prevent recurrence or to radiofrequency ablation, which is approximately 95% curative and has a low risk of complications. It is the preferred method of treatment for most patients.

Complications of AVNRT include hemodynamic compromise, congestive heart failure, syncope, tachycardia-induced angina, cardiomyopathy, myocardial ischemia, and myocardial infarction.

PreviousProceed to Clinical Presentation , Atrioventricular Nodal Reentry Tachycardia

Monday, January 20, 2014

Background

Paroxysmal supraventricular tachycardia (paroxysmal SVT) is an episodic condition with an abrupt onset and termination. (See Etiology and Presentation.)

SVT in general is any tachyarrhythmia that requires atrial and/or atrioventricular (AV) nodal tissue for its initiation and maintenance. It is usually a narrow-complex tachycardia that has a regular, rapid rhythm; exceptions include atrial fibrillation (AF) and multifocal atrial tachycardia (MAT). Aberrant conduction during SVT results in a wide-complex tachycardia. (See Etiology and Workup.)

SVT is a common clinical condition that occurs in persons of all age groups, and treatment can be challenging. Electrophysiologic studies are often needed to determine the source of the conduction abnormalities. (See Epidemiology, Prognosis, Workup, Treatment, and Medication.)

Manifestations of SVT are quite variable; patients may be asymptomatic or they may present with minor palpitations or more severe symptoms. Results from electrophysiologic studies have helped to determine that the pathophysiology of SVT involves abnormalities in impulse formation and conduction pathways. The most common mechanism identified is reentry. (See Etiology, Prognosis, Presentation, and Workup.)[1, 2, 3, 4]

Rare complications of paroxysmal SVT include myocardial infarction, congestive heart failure, syncope, and sudden death. (See Prognosis and Presentation.)

Classification

The development of intracardiac electrophysiologic studies has dramatically changed the classification of SVT, with intracardiac recordings having identified the various mechanisms involved in the condition. Depending on the site of origin of the dysrhythmia, SVT may be classified as an atrial or AV tachyarrhythmia. Another way to separate the arrhythmias is to classify them into conditions having either regular or irregular rhythms.[5, 6]

Atrial tachyarrhythmias include the following:

Sinus tachycardiaInappropriate sinus tachycardia (IST)Sinus nodal reentrant tachycardia (SNRT)Atrial tachycardiaMultifocal atrial tachycardiaAtrial flutterAtrial fibrillation

AV tachyarrhythmias include the following:

AV nodal reentrant tachycardia (AVNRT)AV reentrant tachycardia (AVRT)Junctional ectopic tachycardia (JET)Nonparoxysmal junctional tachycardia (NPJT)Patient education

For patient education information, see the Heart Health Center, as well as Supraventricular Tachycardia (SVT, PSVT), Atrial Fibrillation (A Fib), Atrial Flutter, and Heart Rhythm Disorders.

NextEtiology

SVT and paroxysmal SVT are triggered by a reentry mechanism. This may be induced by premature atrial or ventricular ectopic beats. Other triggers include hyperthyroidism and stimulants, including caffeine, drugs, and alcohol.

Paroxysmal SVT is observed not only in healthy individuals; it is also common in patients with previous myocardial infarction, mitral valve prolapse, rheumatic heart disease, pericarditis, pneumonia, chronic lung disease, and current alcohol intoxication.[7, 8, 9, 10] Digoxin toxicity also may be associated with paroxysmal SVT.[9, 10, 11]

Atrial tachyarrhythmias

Sinus tachycardia

Sinus tachycardia is the most common regular SVT. It has an accelerated sinus rate that is a physiologic response to a stressor. It is characterized by a heart rate faster than 100 beats per minute (bpm) and generally involves a regular rhythm. (See the image below.)

Sinus tachycardia. Note that the QRS complexes areSinus tachycardia. Note that the QRS complexes are narrow and regular. The patient's heart rate is approximately 135 bpm. P waves are normal in morphology.

Underlying physiologic stresses such as hypoxia, hypovolemia, fever, anxiety, pain, hyperthyroidism, and exercise usually induce sinus tachycardia.[12, 13] Certain drugs, such as stimulants (eg, nicotine, caffeine), medications (eg, atropine, salbutamol), recreational drugs (eg, cocaine, amphetamines, ecstasy), and hydralazine, can also induce the condition. Treatment involves addressing the basic underlying stressor.

Inappropriate sinus tachycardia

IST is an accelerated baseline sinus rate in the absence of a physiologic stressor. In this situation, healthy adults may have an elevated resting heart rate and an exaggerated heart rate response to even minimal exercise. This tachyarrhythmia is observed most commonly in young women without structural heart disease.[14, 15, 10]

The underlying mechanism of IST may be hypersensitivity of the sinus node to autonomic input or an abnormality within the sinus node and/or its autonomic input.[14, 15, 10]

Sinus nodal reentrant tachycardia

SNRT is frequently confused with IST. SNRT is due to a reentry circuit, either in or near the sinus node. Therefore, it has an abrupt onset and offset. The heart rate is usually 100-150 bpm, and electrocardiographic tracings usually demonstrate a normal sinus P wave morphology.[14, 15, 10]

Atrial tachycardia

Atrial tachycardia is an arrhythmia originating in the atrial myocardium. Enhanced automaticity, triggered activity, or reentry may result in this rare tachycardia.[16, 17, 18, 19, 10] The heart rate is regular and is usually 120-250 bpm. The P-wave morphology is different from the sinus P waves and is dependent on the site of origin of the tachycardia. (See the image below.)

Atrial tachycardia. The patient's heart rate is 15Atrial tachycardia. The patient's heart rate is 151 bpm. P waves are upright in lead V1.

Because the arrhythmia does not involve the AV node, nodal blocking agents, such as adenosine and verapamil, are usually unsuccessful in terminating this arrhythmia. Atrial tachycardia has also been associated with digoxin toxicity via the triggered mechanism.[16, 17, 18, 19, 10]

Multifocal atrial tachycardia

Multifocal atrial tachycardia is a tachyarrhythmia that arises within the atrial tissue; it is composed of 3 or more P-wave morphologies and heart rates. This arrhythmia is fairly uncommon; it is typically observed in elderly patients with pulmonary disease. The heart rate is greater than 100 bpm, and electrocardiographic findings typically include an irregular rhythm, which may be misinterpreted as atrial fibrillation (see the image below). Treatment involves correcting the underlying disease process.[20, 21, 22] Magnesium and verapamil may sometimes be effective.

Multifocal atrial tachycardia. Note the different Multifocal atrial tachycardia. Note the different P-wave morphologies and irregularly irregular ventricular response.

Atrial flutter

Atrial flutter is a tachyarrhythmia arising above the AV node with an atrial rate of 250-350 bpm. The mechanism behind atrial flutter is generally reentrant in nature. Typically, counterclockwise atrial flutter is due to a macroreentrant right atrial circuit. It is commonly observed in patients with any of the following conditions:

Ischemic heart diseaseMyocardial infarctionCardiomyopathyMyocarditisPulmonary embolusToxic ingestion (eg, alcohol)Chest trauma

Atrial flutter may be a transitional rhythm and can progress to atrial fibrillation. Electrocardiographic findings of typical atrial flutter include negative sawtooth flutter waves in leads II, III, and aVF. AV conduction is most commonly 2:1, which yields a ventricular rate of approximately 150 bpm. (See the image below.)[12, 23, 11]

Atrial flutter. The patient's heart rate is approxAtrial flutter. The patient's heart rate is approximately 135 bpm with 2:1 conduction. Note the sawtooth pattern formed by the flutter waves.

Atrial fibrillation

Atrial fibrillation is an extremely common arrhythmia arising from chaotic atrial depolarization. The atrial rate is usually 300-600 bpm, while the ventricular rate may be 170 bpm or more. Electrocardiographic findings characteristically include an irregular rhythm with fibrillatory atrial activity. (See the image below.)

Atrial fibrillation. The patient's ventricular ratAtrial fibrillation. The patient's ventricular rate varies from 130-168 bpm. The rhythm is irregularly irregular. P waves are not discernible.

This arrhythmia is associated with the following conditions[12, 23, 11] :

Rheumatic heart diseaseHypertensionIschemic heart diseasePericarditisThyrotoxicosisAlcohol intoxicationMitral valve prolapse and other disorders of the mitral valveDigitalis toxicity

When atrial fibrillation occurs in young or middle-aged patients in the absence of structural heart disease or any other apparent cause, it is called lone or idiopathic atrial fibrillation.

AV tachyarrhythmias

AV nodal reentrant tachycardia

The most common cause of paroxysmal SVT is AVNRT. AVNRT is diagnosed in 50-60% of patients who present with regular narrow QRS tachyarrhythmia.[3, 23, 24, 25] The heart rate is 120-250 bpm and is typically quite regular. (See the images below.)

Atrioventricular nodal reentrant tachycardia. The Atrioventricular nodal reentrant tachycardia. The patient's heart rate is approximately 146 bpm with a normal axis. Note the pseudo S waves in leads II, III, and aVF. Also note the pseudo R' waves in V1 and aVR. These deflections represent retrograde atrial activation. Same patient as in the previous image. The patientSame patient as in the previous image. The patient is in sinus rhythm following atrioventricular nodal reentrant tachycardia.

AVNRT may occur in healthy, young individuals, and it occurs most commonly in women.[25] Most patients do not have structural heart disease. However, occasionally these individuals may have an underlying heart condition such as rheumatic heart disease, pericarditis, myocardial infarction, mitral valve prolapse, or preexcitation syndrome.[3, 24, 25]

An understanding of the electrophysiology of AV nodal tissue is very important in comprehending the mechanism of AVNRT. In most people, the AV node has a single conducting pathway that conducts impulses in an anterograde manner to depolarize the bundle of His. In certain cases, AV nodal tissue may have 2 conducting pathways with different electrophysiologic properties. One pathway (alpha) is a relatively slow conducting pathway with a short refractory period, while the second pathway (beta) is a rapid conducting pathway with a long refractory period.

The coexistence of these functionally different pathways serves as the substrate for reentrant tachycardia.[3, 23, 24, 9] Electrophysiologic studies have demonstrated dual AV nodal pathways in 40% of patients.

The onset of AVNRT is triggered by a premature atrial impulse. A premature atrial impulse may reach the AV node when the fast pathway (beta) is still refractory from the previous impulse but the slow pathway (alpha) may be able to conduct. The premature impulse then conducts through the slow pathway (alpha) in an anterograde manner; the fast pathway (beta) continues to recover because of its longer refractory period.

After the impulse conducts in an anterograde manner through the slow pathway (alpha), it may find the fast pathway (beta) recovered. The impulse then conducts in a retrograde manner via the fast (beta) pathway. If the slow pathway (alpha) has repolarized by the time the impulse completes the retrograde conduction, the impulse can reenter the slow pathway (alpha) and initiate AVNRT. (See the image below.)

Image A displays the slow pathway and the fast patImage A displays the slow pathway and the fast pathway, with a regular impulse being conducted through the atrioventricular node. Image B displays a premature impulse that is conducted in an anterograde manner through the slow pathway and in a retrograde manner through the fast pathway, as is seen in typical atrioventricular nodal tachycardia. Image C displays the premature impulse conducting in a retrograde manner through the pathway and the impulse reentering the pathway with anterograde conduction, which is seen commonly in patients with atypical atrioventricular nodal tachycardia.

Importantly, note that AVNRT does not involve the ventricles as part of the reentry circuit; the necessity of perinodal atrial tissue to the circuit is controversial. Because the impulse typically conducts in an anterograde manner through the slow pathway and in a retrograde manner through the fast pathway, the PR interval is longer than the RP interval. Thus, in patients with typical AVNRT, the P wave is usually located at the terminal portion of the QRS complex.[3, 23, 11, 24, 9]

In patients with atypical AVNRT, anterograde conduction is via the fast pathway, while retrograde conduction is via the slow pathway. For these atypical patients, the RP interval is longer than the PR interval.[24, 26, 23, 25, 3, 9, 27, 11]

AV reentrant tachycardia

AVRT is the second most common form of paroxysmal SVT. The incidence rate of AVRT in the general population is 0.1-0.3%. AVRT is more common in males than in females (male-to-female ratio of 2:1), and patients with AVRT commonly present at a younger age than do patients with AVNRT. AVRT is associated with the Ebstein anomaly, although most patients with AVRT do not have evidence of structural heart disease.

AVRT occurs in the presence of accessory pathways, or bypass tracts. Accessory pathways are errant strands of myocardium that bridge the mitral or tricuspid valves.[24, 28, 9, 10]

AVRT results from the presence of 2 or more conducting pathways; specifically, the AV node and 1 or more bypass tracts. In a normal heart, only a single route of conduction is present. Conduction begins at the sinus node, progresses to the AV node, and then to the bundle of His and the bundle branches. However, in AVRT, 1 or more accessory pathways connect the atria and the ventricles. The accessory pathways may conduct impulses in an anterograde manner, a retrograde manner, or both.[29, 30, 24, 31, 28, 32, 9, 10]

When impulses travel down the accessory pathway in an anterograde manner, ventricular preexcitation results. This produces a short PR interval and a delta wave, as is observed in persons with Wolff-Parkinson-White (WPW) syndrome. (See the image below.)[29]

Wolff-Parkinson-White pattern. Note the short PR iWolff-Parkinson-White pattern. Note the short PR interval and slurred upstroke (delta wave) to the QRS complexes.

Importantly, note that not all accessory pathways conduct in an anterograde manner. Concealed accessory pathways are not evident during sinus rhythm, and they are only capable of retrograde conduction.

A reentry circuit is most commonly established by impulses traveling in an anterograde manner through the AV node and in a retrograde manner through the accessory pathway; this is called orthodromic AVRT. (See the image below.)

Orthodromic atrioventricular reentrant tachycardiaOrthodromic atrioventricular reentrant tachycardia. This patient has Wolff-Parkinson-White syndrome.

A reentry circuit may also be established by a premature impulse traveling in an anterograde manner through a manifest accessory pathway and in a retrograde manner through the AV node; this is called antidromic AVRT. While the orthodromic AVRT is typically a narrow-complex tachycardia, antidromic AVRT inscribes a bizarre, wide-complex tachycardia. (See the images below.)[33, 34, 35]

The left image displays the atrioventricular node The left image displays the atrioventricular node with the accessory pathway. The impulse is conducted in an anterograde manner in the atrioventricular node and in a retrograde manner in the accessory pathway. This circuit is known as orthodromic atrioventricular reentrant tachycardia and can occur in patients with concealed accessory tracts or Wolff-Parkinson-White syndrome. The right image displays the impulse being conducted in an anterograde manner through the accessory pathway and in a retrograde manner via the atrioventricular node. This type of circuit is known as antidromic atrioventricular reentrant tachycardia and occurs only in patients with Wolff-Parkinson-White syndrome. Both patterns may display retrograde P waves after the QRS complexes. The left panel depicts antidromic atrioventricularThe left panel depicts antidromic atrioventricular reentrant tachycardia. The right panel depicts sinus rhythm in a patient with antidromic atrioventricular reentrant tachycardia. Note that the QRS complex is an exaggeration of the delta wave during sinus rhythm.

Patients with WPW syndrome can develop atrial fibrillation and atrial flutter (see the image below). The rapid nondecremental conduction via the accessory pathways can result in extremely rapid rates, which can degenerate to ventricular fibrillation and cause sudden death. Patients with preexcitation syndromes with atrial fibrillation must not be administered an AV nodal blocking agent; these agents can further increase conduction via the accessory pathway, which increases the risk of ventricular fibrillation and death.[36, 37, 7, 33, 38, 8, 39]

Atrial fibrillation in a patient with Wolff-ParkinAtrial fibrillation in a patient with Wolff-Parkinson-White syndrome. Note the extremely rapid ventricular rate and variability in QRS morphology. Several minutes later, the patient developed ventricular fibrillation.

Junctional ectopic tachycardia and nonparoxysmal junctional tachycardia

JET and NPJT are rare; they presumably arise because of increased automaticity, triggered activity, or both. They are usually observed following valvular surgery, after myocardial infarction, during active rheumatic carditis, or with digoxin toxicity. These tachycardias are also observed in children following congenital heart surgery. Electrocardiographic findings include a regular narrow QRS complex, although P waves may not be visible. Patients with AV dissociation have also been described.[9, 40, 41]

PreviousNextEpidemiologyOccurrence in the United States

The incidence of paroxysmal SVT is approximately 1-3 cases per 1000 persons. The incidence rate of the WPW pattern on electrocardiographic tracings is 0.1-0.3% in the general population, although not all patients develop SVT.[7, 8, 9, 10, 42]

In a population-based study, the prevalence of paroxysmal SVT was 2.25 cases per 1000 persons, with an incidence of 35 cases per 100,000 person-years.[43] AVNRT is more common in patients who are middle aged or older, while adolescents are more likely to have SVT mediated by an accessory pathway.

Paroxysmal SVT is observed not only in healthy individuals; it is also common in patients with previous myocardial infarction, mitral valve prolapse, rheumatic heart disease, pericarditis, pneumonia, chronic lung disease, and current alcohol intoxication.[7, 8, 9, 10] Digoxin toxicity also may be associated with paroxysmal supraventricular tachycardia.[9, 10, 11]

Sex-related demographics

Most series of catheter ablation reflect a higher proportion of female patients with AVNRT than male patients. This may reflect a true higher incidence in women, or it may reflect the sample of patients who are referred (or choose) to undergo extensive evaluation and/or catheter ablation.

In a population-based study, the risk of developing paroxysmal SVT was twice as high in women as it was in men.[43]

Age-related demographics

The prevalence of paroxysmal SVT increases with age. AVNRT is seen more commonly in persons who are middle aged or older, while adolescents usually have SVT from an accessory pathway.[43] The relative frequency of tachycardia mediated by an accessory pathway decreases with age.

PreviousNextPrognosis

Patients with symptomatic WPW syndrome have a small risk of sudden death. Otherwise, prognosis in paroxysmal SVT is dependent on any underlying structural heart disease; patients with a structurally normal heart have an excellent prognosis.

Morbidity and mortality

Paroxysmal SVT may start suddenly and last anywhere from seconds to days. Patients may or may not be symptomatic, depending on their hemodynamic reserve and heart rate, the duration of the paroxysmal SVT, and coexisting diseases.

Paroxysmal SVT can result in heart failure, pulmonary edema, myocardial ischemia, and/or myocardial infarction secondary to an increased heart rate in patients with poor left ventricular function.[9, 10, 11] In fact, one study found that one third of patients with SVT experienced syncope or required cardioversion.[44] Incessant SVT can cause tachycardia-induced cardiomyopathy.

Patients with WPW syndrome may be at risk for cardiac arrest if they develop atrial fibrillation or atrial flutter in the presence of a rapidly conducting accessory pathway (ie, a pathway with a short anterograde refractory period).

Extremely rapid ventricular rates during atrial fibrillation or atrial flutter can cause deterioration to ventricular fibrillation. This complication is unusual and occurs primarily in patients who have had prior symptoms due to WPW syndrome. Sudden death may be the initial presentation of WPW syndrome, but how often this occurs is unclear.

In the absence of manifest preexcitation (ie, WPW syndrome), the risk of sudden death with paroxysmal SVT is extremely small.

PreviousProceed to Clinical Presentation , Paroxysmal Supraventricular Tachycardia